Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Zeng, Zhen
Ngo, Hung Long
Proctor, Martina
Rizos, Helen
Dolcetti, Riccardo
Cruz, Jazmina Gonzalez
Wells, James W
Gabrielli, Brian
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2023
Size
File type(s)
Location
Abstract

Treatment of melanomas with targeted and immunotherapies has proven effective, but resistance to both treatments is a common outcome leaving a high proportion of patients without effective alternative treatment options. Replication stress is a common feature of melanomas, and this is effectively targeted using a combination of checkpoint kinase 1 (CHK1) inhibitor and low-dose hydroxyurea (LDHU). This combination also promotes inflammatory and anti-tumour immune responses in vivo. Melanoma cell lines resistant to BRAF inhibitor (BRAFi) or immune checkpoint inhibitors (ICI) retain their sensitivity to CHK1i + LDHU, with sensitivity similar to that of parental tumours. In vivo, BRAFi-resistant and BRAFi-sensitive parental tumours produce an identical immune response with treatment.

Journal Title

Pigment Cell & Melanoma Research

Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© 2023 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Item Access Status
Note

This publication has been entered in Griffith Research Online as an advanced online version.

Access the data
Related item(s)
Subject

Biochemistry and cell biology

Genetics

Oncology and carcinogenesis

CHK1 inhibitor

immune response

replication stress

treatment resistance

Persistent link to this record
Citation

Zeng, Z; Ngo, HL; Proctor, M; Rizos, H; Dolcetti, R; Cruz, JG; Wells, JW; Gabrielli, B, Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas, Pigment Cell & Melanoma Research, 2023

Collections